Online Inquiry
FGF Receptor 3 (IIIc)Antibody
SPA-03930
| Size | Price |
| 25 µg | Online Inquiry |
| 100 µg | Online Inquiry |
| More Options | Online Inquiry |
| Target Information | |
|---|---|
| Target Name | FGF Receptor |
| Gene Abbr. | FGFR3 |
| Gene ID | 2261 |
| Full Name | fibroblast growth factor receptor 3 |
| Alias | ACH, CD333, CEK2, HSFGFR3EX, JTK4 |
| Introduction | Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain. Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues. Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling. The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ.Activating mutations within fibroblast growth factor receptor 3 (FGFR-3) are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II. Several of these same FGFR-3 mutations as well as overexpression of FGFR-3 proteins have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma and cervical cancer. Thus, FGFR-3 may represent a potential target for therapy. |
| Product Details | |
|---|---|
| Host | Mouse |
| Clonality | Monoclonal |
| Clone No. | IIIc |
| Isotype | IgG1 |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant human FGF R3 alpha (IIIc). |
| Usage | |
|---|---|
| Application | WB, IHC, IF |
| Dilutions | Western Blot (1 µg/mL); Immunohistochemistry (5-25 µg/mL); Immunofluorescence (8-25 µg/mL) |
| MW(KDa) | 165, 145 and 125 |
| Reactivity | Human |
| Specificity | Detects human FGF R3 (IIIc) in direct ELISAs and Western Blots. In direct ELISAs, 100% cross‑reactivity with with recombinant human (rh) FGF R2 (IIIc), recombinant mouse (rm) FGF R2 (IIIc) and rmFGF R3 (IIIc) is observed. In Western Blots (non-reducing conditions only), 50‑100% cross-reactivity with rhFGF R2 (IIIc), rmFGF R2 (IIIc) and rmFGF R3 (IIIc) is observed. Does not cross-react with the IIIb isoforms of rhFGF R3, rmFGF R3, rhFGF R2 or rmFGF R2. No cross-reactivity with any isoforms of rhFGF RI or rhFGF R4 is observed. |
| Storage & Handling | |
|---|---|
| Storage Buffer | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
| Preservative | No Preservative |
| Storage Temp. | 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Handling | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.